EMA panel recommends approval of Bluebird Bio's first gene therapy
A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Biotechnology | European Medicines Agency (EMA) | Gene Therapy | Genetics | Health | Marketing